Shelby Pirtle Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 703 State Highway 31 E, Chandler, TX 75758 Phone: 903-849-4090 |
Laura Jill Mcgill, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 201 State Highway 31 E, Chandler, TX 75758 Phone: 903-849-6442 Fax: 903-849-5627 |
Dr. Christoper Medina Araiza, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 703 State Hwy 31 W E, Chandler, TX 75758 Phone: 903-849-4090 |
Richard William Limehouse Jr. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 703 Highway 31, Chandler, TX 75758 Phone: 903-849-4090 Fax: 903-849-4129 |
News Archive
Researchers at the University of Pittsburgh School of Dental Medicine have been awarded a $11.8 million, five-year grant from the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health, to continue their exploration of the genetic roots of cleft lip and cleft palate and to expand the effort to include populations in Colombia, Nigeria, the Philippines and Pennsylvania.
A new three-part study showed that a delayed-release, extended-release form of methylphenidate could be given to adults in the evening with or without food and would not exert any clinically meaningful effect for at least 10 hours after administration.
In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.
Driving under the influence of alcohol may not be a good idea because one is not in control. A new study has shown that that driving with a hangover is also not a good idea.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company raised $35.5 million in a Series E financing based on encouraging clinical progress and investor support for galeterone (TOK-001), Tokai's lead prostate cancer drug candidate.
› Verified 8 days ago